ArticleJournal of natural products2011
Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.
Article in Journal of natural products, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 45 citations in OpenAlex.
- Marine life as a source of anti-prostate cancer agents: an updated overview (2003-2023).Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Direct immunoactivation by chemotherapeutic drugs in cancer treatment.Advanced therapeutics · 2023Article
- Antibody-drug conjugates: Recent advances in payloads.Acta pharmaceutica Sinica. B · 2023Review
- Novel Marine Secondary Metabolites Worthy of Development as Anticancer Agents: A Review.Molecules (Basel, Switzerland) · 2021Review
- Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry.Marine drugs · 2021Review
- Cyanobacteria as Natural Therapeutics and Pharmaceutical Potential: Role in Antitumor Activity and as Nanovectors.Molecules (Basel, Switzerland) · 2021Review
- Identification and Characterization of a Novel Protein ASP-3 Purified fromMarine drugs · 2019Article
- Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Review
- The "Utility" of Highly Toxic Marine-Sourced Compounds.Marine drugs · 2019Review
- Palladium-Catalyzed Dehydrogenative Coupling: An Efficient Synthetic Strategy for the Construction of the Quinoline Core.Marine drugs · 2017Article
- Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Marine drugs · 2017Review
- Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.Marine drugs · 2016Review
- Total synthesis and cytotoxicity of the marine natural product malevamide D and a photoreactive analog.Beilstein journal of organic chemistry · 2014Article
- Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.Journal of natural products · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The dolastatin series of unique peptides, originally discovered as constituents of the sea hare Dolabella auricularia, is of increasing importance in providing biological leads, especially to new and useful anticancer drugs. Dolastatin 10 and three analogues, minor structural modifications designated auristatins, are currently in human cancer clinical trials. The present study was undertaken to explore delivery to the cancer sites by way of phosphate or quinoline modifications. The initial objectives, auristatin TP as sodium phosphate 3b (GI50 10(-2)-10(-4) μg/mL), auristatin 2-AQ (4, GI50 10(-2)-10(-3) μg/mL), and auristatin 6-AQ (5, GI50 10(-4) μg/mL), exhibited superior cancer cell growth inhibitory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.